What are the NCCN preferred regimens for treatment of relapsed multiple myeloma (MM)?

Updated: Jul 15, 2019
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

For MM that relapses after more than 6 months, the regimen used for primary induction therapy can be repeated. Otherwise, the NCCN considers the following as preferred regimens for previously treated MM:

  • Bortezomib/lenalidomide/dexamethasone
  • Carfilzomib (twice weekly)/dexamethasone (category 1)
  • Carfilzomib/lenalidomide/dexamethasone (category 1)
  • Daratumumab/bortezomib/dexamethasone (category 1)
  • Daratumumab/lenalidomide/dexamethasone (category 1)
  • Elotuzumab/lenalidomide/dexamethasone (category 1)
  • Ixazomib/lenalidomide/dexamethasone (category 1)

ee Treatment and Medication for more detail.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!